Skip to main content
EJNMMI Radiopharmacy and Chemistry

Table 4 DOTA-to-nuclide molar ratios, corresponding to 50% labeling efficiency of 161Tb-DOTA and both carrier-added and no-carrier-added 177Lu-DOTA over a two-week decay period

From: Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy

Nuclide

Day 3

Day 7

Day 10

Day 14

161Tb (PSI) No-carrier-added

4.4 ± 0.3

5.7 ± 0.4

7.6 ± 0.5

9.4 ± 0.3

177Lu (ITG) No-carrier-added

3.8 ± 0.1

4.2 ± 0.1

5.7 ± 0.1

7.1 ± 0.1

177Lu (IDB) Carrier-added

5.8*

7.5*

9.2*

12.2*

  1. * Statistically different to no-carrier-added 161Tb and 177Lu (p < 0.05)
Back to article page